Immutep Limited (PRRUF)
OTCMKTS · Delayed Price · Currency is USD
0.1940
-0.0180 (-8.49%)
At close: May 29, 2025
Immutep Revenue
Immutep had revenue of 3.15M AUD in the half year ending December 31, 2024, with 86.75% growth. This brings the company's revenue in the last twelve months to 4.88M, up 24.11% year-over-year. In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M with 9.59% growth.
Revenue (ttm)
4.88M AUD
Revenue Growth
+24.11%
P/S Ratio
82.48
Revenue / Employee
157.38K AUD
Employees
31
Market Cap
249.02M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Immutep News
- 2 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 2 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 2 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 4 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire
- 6 months ago - Immutep Limited: Continuing To Make The Case For Eftilagimod - Seeking Alpha
- 7 months ago - Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewsWire
- 8 months ago - Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 - GlobeNewsWire